|Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 517 active entries
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Jerini AG is a Berlin-based biopharmaceutical company focusing on peptide-originated drug discovery and development. The company is structured into two business units: Jerini Pharmaceuticals (JPH) and Jerini Peptide Technologies (JPT).
JPH develops drugs in own or partnered programs with emphasis on difficult targets not amenable to conventional methods. The current portfolio ranges from preclinical to advanced clinical projects in Phase IIa trials. Currently, the company has two ongoing Phase IIa clinical trials conducted with Icatibant JE049, a peptidomimetic Bradykinin receptor antagonist. The first study was initiated in August 2002 for decompensated liver cirrhosis with resistant ascites. In February 2003, the second clinical Phase II study was initiated for angioedema, for the treatment of which Jerini has been granted orphan drug status by the EMEA and FDA. Preclinical pipeline: The preclinical pipeline comprises six discovery programs two of which are partnered aiming at the development of peptidomimetics and small molecules against inflammation and oncology targets.
JPT is an independently operated, profitable business unit of Jerini that sells high end peptide-based research tools to universities, biotech and pharma companies. JPT offers a broad range of peptide-related custom products and services for applications in immunology, proteomics and drug discovery. Using its proprietary chip-based high throughput peptide synthesis and screening platform, JPT offers its customers a wide portfolio of high end peptide products including peptide micro-arrays for kinase and protease profiling. Between 2.000 to 20.000 molecules can be synthesized in parallel in a fully automated process. JPT’s technology platform has been validated worldwide by reference customers in academia and industry.
The company is backed by an international consortium of investors (3i, TVM, Polytechnos, IBB Beteiligungsgesellschaft mbH, SandersMorrisHarris, Technologie Beteiligungsgesellschaft and bmp AG).
Last update of this entry: February 27, 2004